

October 29, 2026

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
--	--

Sub: **Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Acquisition**

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform that the Board of Directors of the Company at its meeting held today, i.e., on October 29, 2026, *inter alia*, has approved for acquisition of 60% share capital of Galenvs Sciences Inc. (“Galenvs”), a Canada based company, at a pre-money valuation of USD 3.50 million. The Company proposes to invest a total of USD 3.75 million, which includes primary infusion of USD 2.75 million and a secondary acquisition of USD 1.00 million (the “Proposed Transaction”).

Galenvs is a contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. It operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production.

The Proposed Transaction is contemplated by way of:

- primary subscription to 8,092,857 common shares of the Galenvs at an aggregate consideration of USD 2.75 million, equivalent to 44% of the post-issue paid-up equity capital of Galenvs on diluted basis; and
- secondary acquisition of 2,942,857 common shares of Galenvs at an aggregate consideration of USD 1.00 million from the Founder shareholder, equivalent to 16% of the post-issue paid-up equity capital of Galenvs on diluted basis.

Following such acquisition pursuant to (a) and (b) above, the Company shall hold 60% of the common share capital of the Galenvs on diluted basis and Galenvs will be a subsidiary company of the Company. Further, the Galenvs has one wholly owned subsidiary, namely, Galenvs Solutions Inc, and consequently, post-acquisition it will become step-down wholly owned subsidiary of the Company.

The disclosure pursuant to Regulation 30 of the SEBI Listing Regulations read with Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith in Annexure-A.

The Board Meeting commenced at 02.00 p.m. (IST) and concluded at 02.47 p.m. (IST).

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District – 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana – 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Please take the above information on record.

Thanking you.

Yours faithfully,

For Laurus Labs Limited

VANTARAM
VENKATA RAVI
KUMAR

Digitally signed by
VANTARAM VENKATA RAVI
KUMAR
Date: 2026.10.29 14:57:34
+05'30'

V V Ravi Kumar

Executive Director and CFO

DIN: 01424180

Encl: A/a

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

a	Name of the target entity, details in brief such as size, turnover etc.	<u>Name of the target entity</u> Galenvs Sciences Inc. (“Galenvs”) situated at Montréal, Canada. <u>Details in brief</u> Galenvs is a Montréal, Canada, based contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. It operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production. <u>Turnover:</u> Calendar Year (CY) 2025 - Canadian \$ 1.65 million
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The acquisition would not fall within related party transaction. The promoter/ promoter group/ group companies of the Company have no interest in Galenvs.
c	Industry to which the entity being acquired belongs	Galenvs is a precision contract research and development organization (CRO/ CDMO).
d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed investment in Galenvs will bring synergy to the business of the Company and Galenvs to develop new markets for its products. While Galenvs will be engaged in Discovery, Lead Optimization and Pre-clinical process development from 1 µmol to 10 mmol, and will transfer the technology to the Company for Phase I/ II/ III of clinical trials and for Commercialization for scale up. The Company will gain for R&D pipeline arm for oligonucleotides, depth on a line already exists, process IP and know-how and a North American business growth opportunity.
e	Brief details of any governmental or regulatory approvals required for the acquisition	The acquisition will be in accordance with the applicable provisions of the FEMA and Regulations made thereunder. Further, the Company will make applicable regulatory filings with the relevant authorities, as may be required under applicable laws.
f	Indicative time period for completion of the acquisition	The Proposed Transaction is expected to be completed during the current financial year, subject to the completion of customary closing conditions and agreements.

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

g	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
h	Cost of acquisition and/or the price at which the shares are acquired	The Proposed Transaction is contemplated by way of: a. primary subscription to 8,092,857 common shares of the Galenvs at a consideration of USD 2.75 million, equivalent to 44% of the post-issue paid-up equity capital of Galenvs on diluted basis; and b. secondary acquisition from Founder shareholder of 2,942,857 common shares of Galenvs at a consideration of USD 1.00 million, equivalent to 16% of the post-issue paid-up equity capital of Galenvs on diluted basis.
i	Percentage of shareholding / control acquired and / or number of shares acquired	The Company will hold 60% shareholding on closing of the Proposed Transaction. Further, remaining shares of Galenvs can be acquired by the Company from the Founder on milestone basis in future.
j	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<u>Brief background and line of business:</u> Galenvs is a Montréal (Canada) based precision contract research and development organization (CRO/ CDMO) specializing in custom oligonucleotide synthesis and functional magnetic-nanoparticle (MNP) technologies for the diagnostics and therapeutics markets. The Company operates a vertically integrated platform spanning discovery, optimization, synthesis, purification, validation and pilot-scale production. Galenvs operates R&D and laboratory facilities in Montréal supporting oligonucleotide synthesis, purification, analytical testing, magnetic nanoparticle development and related process development activities. <u>Date of incorporation:</u> 26 September 2016 <u>Turnover of last 3 years:</u> Turnover as per last latest financials are as follows: • CY2025: Canadian \$ 1.65 million • CY2024: Canadian \$ 1.28 million • CY2023: Canadian \$ 1.36 million <u>Country in which the entity has presence:</u> Galenvs has business operations in Montréal, Canada and it has presence in North America.

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anaparthi District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518